Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 0.32 |
| ▸ | POLG | P54098 | 2/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.31 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17232097 | 1.00 | ALB (0.32) | ALBPOLGCACNA1FLMNAMAPT | |
| SCHEMBL15369632 | 0.84 | ALB (0.46) | ALBCACNA1FLMNAMAPTCACNA1D | |
| SCHEMBL19871162 | 0.84 | — | — | |
| SCHEMBL17232087 | 0.79 | POLG (0.34) | ALBPOLG | |
| SCHEMBL19871149 | 0.79 | — | — | |
| SCHEMBL17232098 | 0.78 | — | — | |
| SCHEMBL17232084 | 0.76 | — | — | |
| SCHEMBL19871163 | 0.72 | — | — | |
| SCHEMBL19871157 | 0.72 | — | — | |
| SCHEMBL19871147 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263114-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2016-09-15 | — | — | US | disclosed |
| US-9326983-B2 | Compositions and methods for treating retinal degradation | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150038446-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263114-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | ALDH1A2, UNG, DNASE1L3 | ALB 4270/4885POLG 57/4885CACNA1F 4861/4885 |
| US-20150038446-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | ALDH1A2, UNG, DNASE1L3 | ALB 4270/4885POLG 57/4885CACNA1F 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.